Why:
- The profit jump being sold has unsold stock inside it. FY2026 profit grew 43.9% on the books, but the entire year's finished-goods build (₹5.99 crore to ₹9.53 crore) happened in the last quarter, funded by 60-89 day borrowings, while customer advances collapsed from ₹1.17 crore to ₹0.12 crore — the previous year's build was order-backed, this one is not (T1). Corrected for basis errors the underlying year is decent (sold volume up ~7% a year, spread widening modestly), but the question the buyer needs answered — did that stock sell through after March — the filing cannot answer.
- No protection anywhere in the chain. One unnamed supplier is 63-68% of purchases and rising, on spot terms; one creditor holds 55% of payables; there are no contracts on either side; Maharashtra produced 104% of two years' revenue growth while exports fell three years running; and the PE-foam line lost share for three years in a market growing ~4.5% (T1/T3). A same-size competitor is growing four times faster, and — settled from the registry trail — a promoter's brother runs Heera Roto Compounds, an active rival whose catalogue overlaps ~84% of Phychem's revenue lines, excluded from the filing's group-company chapter (T1/T4).
- The cap table's last price was set among insiders. Three weeks before the RHP the promoters sold ₹1.18 crore of shares at ₹52 — before any band existed — and at least 43% of it went to promoter family members, a serving senior manager, and the company's own independent director, who bought 14 days after ceasing office (T1). Weeks earlier, 30.1% of the capital moved as intra-family gifts. All disclosed, at the regulatory minimum, at exactly the points a reader most needs context.
Valuation at the band
| Floor ₹51 (T1) | Cap ₹54 (T1) | |
|---|---|---|
| Bid window | 31 Aug to 2 Sep 2026 | |
| Bid lot | 4,000 shares (then multiples of 2,000) | |
| Post-issue shares | 1,02,40,000 | 1,02,40,000 |
| Market capitalisation | ₹52.2 cr | ₹55.3 cr |
| P/E as printed (pre-issue EPS) | 9.41x | 9.96x |
| P/E on post-issue shares | 12.8x | 13.5x |
| Weighted average RoNW (corrigendum) | 28.71% | 28.71% |
| Promoter group holding after | 64.05% | 64.05% |
The printed P/E uses the pre-issue share count; the post-issue row is the multiple a buyer actually pays. Cheap-looking either way — priced off the FY2026 profit whose quality is the first bullet above.
The story
You are buying a real, growing niche compounder with a third of its plant idle and genuine operating leverage if it fills — and, stapled to it, an unprotected supply chain, a one-state revenue base, a pre-IPO year whose profit sits partly in unsold stock, and a promoter family whose relatives run a lookalike competitor and bought the pre-IPO shares themselves.
What this business is
Phychem, at Dindori near Nashik, grinds and compounds polyethylene into the powders that rotational moulders turn into water tanks: colour powders (46% of revenue), stone-effect compounds (23%), PE foam (15%), plus smaller lines and trading. FY2026 revenue ₹56.5 crore, profit ₹4.1 crore, RoNW near 30% on just ₹29 lakh of equity ever paid in. The plant runs at 65% of its 6,000-tonne capacity; filling the idle third would add roughly ₹6.4 crore of gross profit against ₹6.1 crore of current EBITDA.
Easy or difficult business? Grinding and colour-matching commodity polymer. The skills are real (formulation, consistency, changeover management) but the structure is open: machinery vendors sell the same capability inside turnkey tank plants, large moulders insource it as they scale, and the industry is a fragmented tail of small compounders with an 18x-scale listed player able to enter at will.
Key numbers
| ₹ cr | FY2024 | FY2025 | FY2026 |
|---|---|---|---|
| Revenue | 47.0 | 50.3 | 56.5 |
| Revenue growth % | n/a | 7.1 | 12.2 |
| EBITDA | 2.8 | 4.4 | 6.1 |
| EBITDA margin % | 5.9 | 8.7 | 10.8 |
| PAT | 1.7 | 2.8 | 4.1 |
| PAT growth % | n/a | 67.8 | 43.9 |
The margin climb is flattered by the accounting of the year-end stock build; measured before the inventory line, gross margin was roughly flat across the window. FY2026 operating cash flow was ₹0.78 crore against ₹4.09 crore of profit, and about zero excluding a one-off insurance settlement. On the credit side: ₹2.2 crore of borrowings were repaid between March and July 2026 with no new money.
| Product line, ₹ cr | FY2024 | FY2025 | FY2026 |
|---|---|---|---|
| Colour powders | 17.7 | 22.7 | 25.7 |
| Stone-effect compound | 10.2 | 11.2 | 13.0 |
| PE foam compound | 11.9 | 10.4 | 8.6 |
| Other compounds | 3.1 | 2.8 | 3.3 |
| Tanks, trading and other | 4.1 | 3.2 | 5.8 |
"Other Trading", an undefined bucket inside the last row, jumped 7x to ₹2.9 crore in FY2026 and is never explained.
Scorecard
| Block | Rating | Why |
|---|---|---|
| Right to win | MARGINAL | A functioning niche operator — volume compounding ~7% a year, ~142 repeat customers, all-India standing in the rotomoulders' trade body — with no moat: dominant spot-terms supplier, no contracts, one state producing all the growth, a foam line losing share in a growing market, distribution relationships that are real but not exclusive, and a promoter's brother running an 84%-overlap competitor. |
| Industry and TAM | MARGINAL | The only market number that exists is a trade-body figure whose growth rate is probably a decade stale. Headroom is real (Phychem is ~2% of the pool, a third of its plant idle), but the structure runs against independent compounders: fragmented rivals, faster-growing peers, customers who insource pulverising as they scale, and a giant able to enter. |
| Financial momentum | MARGINAL | Better than it first looks (the "input windfall" was an arithmetic artifact; realisation held; debt is being repaid) and worse where it counts: the Q4 stock build with no orders behind it, near-zero underlying operating cash in FY2026, and an IPO working-capital ask sized on ~42% growth the company has never approached. |
| Risks, governance, RPTs | MARGINAL | Nothing pending against anyone, clean flags — and a habit of minimum compliance: ₹1.06 crore owed to micro/small suppliers with statutory interest accrued and never paid, 16 late filings, an admitted charge-registration breach, TDS defaults in five years, and a corrigendum that fixed the RHP's own anchor-allocation breach four days before opening. |
| Promoter and cap table | MARGINAL | Money runs inward (factory leased from family at ₹1.2 lakh a year, home mortgaged for company lines, loans shrinking) and the scaling arc is genuinely strong. Against that: the insider-heavy ₹52 secondary before any band existed, 30% of capital gifted within the family weeks before the bonus, three contradictory shareholding disclosures, and the undisclosed family-run competitor. |
| Offer structure | PASS | All fresh, no OFS, full lock-in, a benign debt object with documented use, GCP tightly bounded, capex itemised to named vendors. Cautions: the working-capital object's sizing is contested (₹0.8-3.0 crore defensible range), a third of the machinery serves a 2.8%-of-sales line, and nothing is ordered yet. |
Watch out for
- The H1 FY2027 stock answer. If the ₹5.6 crore of FY2026 finished goods sold through at carrying value, the profit is real and this verdict is too harsh; if it discounts or ages, FY2026 was borrowed from FY2027.
- Heera Roto Compounds. A promoter-relative competitor with a ₹10-50 crore revenue band; its registry filings would size how much business sits outside the listed entity's perimeter.
- The 42% plan. The working-capital object needs FY2027 revenue near ₹80 crore against a 7-12% track record and no order book.
The offer
- Raising ₹13.8 to ₹14.6 crore at the band, all fresh issue, no offer for sale (T1).
- For ₹5.15 crore of machinery (targeting the custom-tank and new nylon lines), ₹3.0 crore of working capital, ₹2.5 crore of debt repayment, and bounded general corporate purposes (T1).
- Implied valuation ₹52.2 to ₹55.3 crore, from the table above.
- Promoters hold 86.99% before and 64.05% after, selling nothing in the offer; they sold ₹1.18 crore privately at ₹52 on 1 August 2026, ~3.5% of their holdings, largely to family and insiders (T1).
Assessed from the RHP and corrigendum with outside checks on polymer prices, the market, competitors and the people. Numbers carry source tiers: (T1) the filing's audited/certified sections and exchange records, (T3) trade press and secondary sources, (T4) directories and aggregators, DERIVED where computed from cited inputs. Not a recommendation. The valuation section states what the announced band implies and is not a view on whether that price is right.